Chronic Beneficial Effects of Type 1 Angiotensin II Receptor Antagonist in Patients with Chronic Hypoxemic Pulmonary Diseases

[1]  H. Naruse,et al.  Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[2]  S. Kakutani,et al.  Plasma brain natriuretic peptide levels in normotensive type 2 diabetic patients without cardiac disease. , 2000, Diabetes care.

[3]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[4]  M. Bando,et al.  Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. , 1999, Respiratory medicine.

[5]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[6]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[7]  R. T. Lie,et al.  Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. , 1996, Circulation.

[8]  Mark A. Hlatky,et al.  Guidelines for the Evaluation and Management of Heart Failure Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure) , 1995 .

[9]  K. Kugiyama,et al.  Localization and Mechanism of Secretion of B‐Type Natriuretic Peptide in Comparison With Those of A‐Type Natriuretic Peptide in Normal Subjects and Patients With Heart Failure , 1994, Circulation.

[10]  E. Fleck,et al.  Hemodynamic and Neurohormonal Effects of the Angiotensin II Antagonist Losartan in Patients With Congestive Heart Failure , 1993, Circulation.

[11]  Michihisa Jougasaki,et al.  Different Secretion Patterns of Atrial Natriuretic Peptide and Brain Natriuretic Peptide in Patients With Congestive Heart Failure , 1993, Circulation.

[12]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[13]  S. Yasui,et al.  Acute effects of oral captopril on hemodynamics in patients with cor pulmonale. , 1986, Japanese circulation journal.

[14]  D. Górecka,et al.  Captopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale. , 1986, Chest.

[15]  B. Lipworth,et al.  Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. , 1997, Cardiovascular research.

[16]  G. Rizzato,et al.  Effects of captopril on hemodynamics and blood gases in chronic obstructive lung disease with pulmonary hypertension. , 1986, Respiration; international review of thoracic diseases.